Immunomedics

OverviewSuggest Edit

Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer. Its technologies allow creating humanized antibodies that can be used either alone in unlabeled or naked form or conjugated with radioactive isotopes, chemotherapeutics, cytokines, or toxins.

TypePublic
Founded1982
HQMorris Plains, NJ, US
Websiteimmunomedics.com
Employee Ratings2.9

Latest Updates

Employees (est.) (Dec 2019)366(+6%)
Revenue (FY, 2019)$295 K(-86%)
Share Price (Oct 2020)$87.9
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Immunomedics

Behzad Aghazadeh

Behzad Aghazadeh

Executive Chairman of the Board of Directors
Usama Malik

Usama Malik

Chief Financial Officer, Chief Business Officer
Brendan Delaney

Brendan Delaney

Chief Commercial Officer
Kurt Andrews

Kurt Andrews

Chief Human Resources Officer
Jared Freedberg

Jared Freedberg

General Counsel and Corporate Secretary
Bryan Ball

Bryan Ball

Chief Quality Officer
Show more

Immunomedics Office Locations

Immunomedics has offices in Morris Plains and Rödermark
Morris Plains, NJ, US (HQ)
300 The American Rd
Rödermark, DE
Paul-Ehrlich-Straße 22/D1
Show all (2)

Immunomedics Financials and Metrics

Immunomedics Revenue

Embed Graph
View revenue for all periods
Immunomedics's revenue was reported to be $295 k in FY, 2019 which is a 86.3% decrease from the previous period.
USD

Revenue (Q2, 2020)

20.1m

Gross profit (Q2, 2020)

18.4m

Gross profit margin (Q2, 2020), %

91.7%

Net income (Q2, 2020)

(66.5m)

EBIT (Q2, 2020)

(53.0m)

Market capitalization (26-Oct-2020)

20.3b

Closing stock price (26-Oct-2020)

87.9

Cash (30-Jun-2020)

971.2m

EV

19.3b
Immunomedics's current market capitalization is $20.3 b.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

3.1m2.2m295.0k

Revenue growth, %

(4%)(30%)(86%)

Cost of goods sold

482.7k613.6k

Gross profit

2.6m1.5m295.0k
Half Year
USDH2, 2018

Sales and marketing expense

19.8m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

690.5k597.3k482.2k20.1m

Cost of goods sold

70.2k496.6k46.8k1.7m

Gross profit

620.3k100.7k435.4k18.4m

Gross profit Margin, %

90%17%90%92%
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

43.4m612.1m608.6m

Accounts Receivable

488.7k45.8k295.0k

Prepaid Expenses

891.3k3.8m21.8m

Inventories

580.0k
Half Year
USDH2, 2018

Cash

492.9m

Prepaid Expenses

5.4m

Current Assets

504.5m

PP&E

23.5m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

43.0m61.0m306.7m580.6m437.9m427.9m364.7m536.3m971.2m

Accounts Receivable

427.2k343.3k195.0k22.3m

Prepaid Expenses

5.1m4.7m4.3m8.5m4.9m8.3m7.6m17.3m21.1m

Inventories

527.7k43.3k20.8m
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

(153.3m)(273.9m)(357.3m)

Depreciation and Amortization

923.3k1.3m3.8m

Inventories

(196.0k)580.0k

Accounts Payable

15.8m(1.5m)30.0m
Half Year
USDH2, 2018

Net Income

(157.7m)

Depreciation and Amortization

2.1m

Accounts Payable

1.4m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(118.8m)(121.3m)(156.8m)(64.2m)(87.4m)(163.4m)(257.7m)(93.1m)(159.6m)

Depreciation and Amortization

212.5k627.7k940.3k591.0k804.0k1.8m2.8m960.0k1.9m

Inventories

580.0k(20.8m)

Accounts Payable

(9.5m)
USDFY, 2017

Revenue/Employee

23.6k

Debt/Equity

-3.2 x

Debt/Assets

1.2 x

Financial Leverage

-2.7 x
Show all financial metrics

Immunomedics Operating Metrics

Immunomedics's Properties was reported to be 2 in FY, 2019.
FY, 2017FY, 2018FY, 2019Sep, 2020

Patents (US)

390

Phase I Trials Products

12

Phase III Trials Products

124

Properties

232

Immunomedics Acquisitions / Subsidiaries

Company NameDateDeal Size
IBC Pharmaceuticals, Inc.
Immunomedics GmbH

Immunomedics Revenue Breakdown

Embed Graph

Immunomedics revenue breakdown by business segment: 15.3% from License fee and other revenues, 15.1% from Research and development and 69.6% from Product sales

Human Capital Metrics

Embed Graph

Immunomedics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

Immunomedics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Immunomedics Online and Social Media Presence

Embed Graph

Immunomedics Company Culture

  • Compensation

    D

    55/100

Learn more on Comparably

Immunomedics News and Updates

Global Antibody Drug Conjugates Market Research 2021 Featuring Major Players - Bayer, Concortis Biotherapeutics, F. Hoffman-La Roche, Immunomedics, and Oxford BioTherapeutics

Dublin, Oct. 20, 2021 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering. The global antibody drug conjugates market is expected to grow from $2.34 billion in 2020 to $2.6 billi…

Portnoy Law Firm: Tactile Systems Technology, Inc., Pintec Technologies Holdings Limited, and Immunomedics, Inc. Investors Have Limited Amount of Time Before Class Action Deadline

Investors with losses are encouraged to contact Attorney Lesley F. Portnoy. Investors with losses are encouraged to contact Attorney Lesley F. Portnoy.

Immunomedics Announces FDA Orphan Drug Designation of Trodelvy™ for Adult and Pediatric Glioblastoma

MORRIS PLAINS, N.J., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administ…

Immunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy™ in Metastatic Urothelial Cancer

Trodelvy achieves a 27 percent overall response rate and a 5.9-month median duration of response in heavily-pretreated patients with metastatic urothelial cancer (mUC)

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Immunomedics, Inc. - IMMU

NEW YORK, Sept. 18, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Immunomedics, Inc. ("Immunomedics" or the "Company") (IMMU)...

Immunomedics Announces Encouraging Early-Stage Clinical Results with Trodelvy™ in Brain Cancers

Results include partial responses in small cohort of patients with brain metastasis from breast cancer (BMBC) and recurrent glioblastoma (rGBM) Results include partial responses in small cohort of patients with brain metastasis from breast cancer (BMBC) and recurrent glioblastoma (rGBM)
Show more

Immunomedics Blogs

Head of Quality

Head of Quality Anonymous (not verified) Mon, 02/08/2021 - 18:08 1773 GxP Quality & Compliance Full-Time Exempt Salary (30+ Hours) Apply Now US - NJ - Morris Plains 1 month ago …

Director, Site Supply Chain

Director, Site Supply Chain Anonymous (not verified) Mon, 02/08/2021 - 18:08 1771 Supply Chain Full-Time Exempt Salary (30+ Hours) Apply Now US - NJ - Morris Plains 1 month ago …

Medical Science Liaison - MSL - (NY/NJ) - Oncology

Medical Science Liaison - MSL - (NY/NJ) - Oncology Anonymous (not verified) Mon, 02/01/2021 - 17:25 1756 Medical Affairs Full-Time Non-Exempt Hourly (30+ Hours) Apply Now US - NY 3 months ago …

Associate Director, CMC Regulatory Affairs - Biologics

Associate Director, CMC Regulatory Affairs - Biologics Anonymous (not verified) Thu, 01/21/2021 - 16:36 1757 Regulatory Full-Time Exempt Salary (30+ Hours) Apply Now US - NJ - Morris Plains 3 …

Quality Control Scientist

Quality Control Scientist Anonymous (not verified) Tue, 01/12/2021 - 15:42 1767 GxP Quality & Compliance Full-Time Exempt Salary (30+ Hours) Apply Now US - NJ - Morris Plains 4 weeks ago …

Oncology Account Manager - Pittsburgh

Oncology Account Manager - Pittsburgh Anonymous (not verified) Wed, 01/06/2021 - 15:18 1763 Sales Full-Time Exempt Salary (30+ Hours) Apply Now US - PA - Pittsburgh 1 month ago …
Show more

Immunomedics Frequently Asked Questions

  • When was Immunomedics founded?

    Immunomedics was founded in 1982.

  • Who are Immunomedics key executives?

    Immunomedics's key executives are Behzad Aghazadeh, Usama Malik and Brendan Delaney.

  • How many employees does Immunomedics have?

    Immunomedics has 366 employees.

  • What is Immunomedics revenue?

    Latest Immunomedics annual revenue is $295 k.

  • What is Immunomedics revenue per employee?

    Latest Immunomedics revenue per employee is $806.

  • Who are Immunomedics competitors?

    Competitors of Immunomedics include Novartis, ImmunoGen and AstraZeneca.

  • Where is Immunomedics headquarters?

    Immunomedics headquarters is located at 300 The American Rd, Morris Plains.

  • Where are Immunomedics offices?

    Immunomedics has offices in Morris Plains and Rödermark.

  • How many offices does Immunomedics have?

    Immunomedics has 2 offices.